Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-01T09:40:10.420Z Has data issue: false hasContentIssue false

Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program

Published online by Cambridge University Press:  01 September 2022

A. Clayton*
Affiliation:
University of Virginia School of Medicine, Department Of Psychiatry And Neurobehavioral Sciences, Charlottesville, United States of America
A.J. Cutler
Affiliation:
SUNY Upstate Medical University, Department Of Psychiatry, Syracuse, United States of America
K.M. Deligiannidis
Affiliation:
Zucker Hillside Hospital, Department Of Psychiatry, Glen Oaks, United States of America
R. Lasser
Affiliation:
Sage Therapeutics, Inc, Clinical Development, Cambridge, United States of America
A.J. Sankoh
Affiliation:
Sage Therapeutics, Inc, Data Science, Cambridge, United States of America
J. Doherty
Affiliation:
Sage Therapeutics, Inc, Clinical Development, Cambridge, United States of America
M. Kotecha
Affiliation:
Biogen, Clinical Development, Cambridge, United States of America
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antidepressants that offer a rapid onset of action without requiring chronic use are greatly needed in both major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational, oral, neuroactive steroid and GABAA receptor positive allosteric modulator in clinical development as a 2-week treatment course for MDD and PPD.

Objectives

To present the efficacy and safety of zuranolone vs placebo in Phase 2 and 3 trials.

Methods

In the studies presented (Table 1), improvements in depressive symptoms were assessed by least-squares mean (LSM) using a mixed-effects model for repeated measures on the change from baseline (CFB) at Day 15 in the 17-item Hamilton Rating Scale for Depression total score (HAMD-17; primary endpoint for all trials) and the Montgomery–Åsberg Depression Rating Scale (MADRS; secondary endpoint) following a 14-day treatment course of once-daily zuranolone.

Results

Compared with placebo, zuranolone treatment led to rapid improvements in depressive symptoms across clinical trials, with significant improvements (LSM treatment difference [SE] in CFB) in HAMD-17 and MADRS scores at Day 15 in 3 of the 4 trials (Table 2). Common treatment-emergent adverse events (≥5% in zuranolone treatment arms) were headache, somnolence, dizziness, nausea, sedation, diarrhea, upper respiratory tract infection, and fatigue (Table 3). No incidences of loss of consciousness or excessive sedation were observed.

Conclusions

Across the completed studies in the zuranolone clinical trial program, patients receiving zuranolone consistently experienced improvement in depressive symptoms following a 2-week treatment course. Treatment with zuranolone was generally well tolerated with a consistent safety and tolerability profile.

Disclosure

The MDD-201B, MOUNTAIN, and ROBIN studies were sponsored by Sage Therapeutics, Inc; the WATERFALL study was sponsored by Sage Therapeutics, Inc, and Biogen. Medical writing and editorial support were provided by MediTech Media, Ltd, and funded by Biogen.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.